Table 3.
Theraputic effectiveness comparison between camrelizumab plus apatinib and hepatic artery infusion chemotherapy group and camrelizumab plus apatinib and hepatic artery infusion chemotherapy-microwave ablation group
|
Variables
|
TRIPLET group (n = 122)
|
TRIPLET-MWA group (n = 95)
|
P value
|
TRIPLET group (n = 82)
|
TRIPLET-MWA group (n = 82)
|
P value
|
| Hepatic response | ||||||
| Tumor response to the first TRIPLET | 0.062 | 0.120 | ||||
| Non-OR | 90 (73.77) | 54 (60.67) | 58 (70.73) | 45 (57.69) | ||
| OR | 32 (26.23) | 35 (39.33) | 24 (29.27) | 33 (42.31) | ||
| The optimal tumor response | < 0.001 | 0.007 | ||||
| Non-OR | 38 (31.15) | 9 (9.47) | 21 (25.61) | 7 (8.54) | ||
| OR | 84 (68.85) | 86 (90.53) | 61 (74.39) | 75 (91.46) | 0.006 | |
| Overall response | 0.001 | |||||
| Non-OR | 46 (37.70) | 15 (15.79) | 28 (34.15) | 12 (14.63) | ||
| OR | 76 (62.30) | 80 (84.21) | 54 (65.85) | 70 (85.37) | ||
| HAIC sessions1 | 4 (2, 6) | 4 (2, 6) | 1.000 | 4 (2, 6) | 4 (2, 6) | 1.000 |
| Interval between TRIPLET and MWA, day1 | 40 (32, 53) | 36 (32, 48) |
1
The qualitative data using median with interquartile range in two groups were compared by using the χ2 test.
Data are number of patients; data in parentheses are percentage unless otherwise indicated and data in bracket was percent of patients. TRIPLET: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy; HCC: Hepatocellular carcinoma; HAIC: Hepatic arterial infusion chemotherapy; MWA: Microwave ablation; PSM: Propensity score match; OR: Objective response.